<?xml version="1.0"  ?><!DOCTYPE pmc-articleset PUBLIC "-//NLM//DTD ARTICLE SET 2.0//EN" "https://dtd.nlm.nih.gov/ncbi/pmc/articleset/nlm-articleset-2.0.dtd"><pmc-articleset><article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:ali="http://www.niso.org/schemas/ali/1.0/" xml:lang="en" article-type="research-article" dtd-version="1.4"><!--The publisher of this article does not allow downloading of the full text in XML form.--><front><journal-meta><journal-id journal-id-type="nlm-ta">J Subst Use Addict Treat</journal-id><journal-id journal-id-type="iso-abbrev">J Subst Use Addict Treat</journal-id><journal-id journal-id-type="pmc-domain-id">319</journal-id><journal-id journal-id-type="pmc-domain">nihpa</journal-id><journal-title-group><journal-title>Journal of substance use and addiction treatment</journal-title></journal-title-group><issn pub-type="ppub">2949-8767</issn><issn pub-type="epub">2949-8759</issn><custom-meta-group><custom-meta><meta-name>pmc-is-collection-domain</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-collection-title</meta-name><meta-value>NIHPA Author Manuscripts</meta-value></custom-meta></custom-meta-group></journal-meta><article-meta><article-id pub-id-type="pmcid">PMC12002408</article-id><article-id pub-id-type="pmcid-ver">PMC12002408.1</article-id><article-id pub-id-type="pmcaid">12002408</article-id><article-id pub-id-type="pmcaiid">12002408</article-id><article-id pub-id-type="manuscript-id">NIHMS2067490</article-id><article-id pub-id-type="pmid">39243979</article-id><article-id pub-id-type="doi">10.1016/j.josat.2024.209511</article-id><article-id pub-id-type="manuscript-id-alternative">NIHMS2067490</article-id><article-id pub-id-type="manuscript-id-alternative">NIHPA2067490</article-id><article-version article-version-type="pmc-version">1</article-version><article-categories><subj-group subj-group-type="heading"><subject>Article</subject></subj-group></article-categories><title-group><article-title>Buprenorphine Discontinuation in Telehealth-Only Treatment for Opioid Use Disorder: A Longitudinal Cohort Analysis</article-title></title-group><contrib-group><contrib contrib-type="author"><name name-style="western"><surname>Chan</surname><given-names initials="B">Brian</given-names></name><degrees>MD MPH</degrees><xref rid="A1" ref-type="aff">1</xref><xref rid="A2" ref-type="aff">2</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Cook</surname><given-names initials="R">Ryan</given-names></name><degrees>PhD</degrees><xref rid="A1" ref-type="aff">1</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Levander</surname><given-names initials="X">Ximena</given-names></name><degrees>MD MCR</degrees><xref rid="A1" ref-type="aff">1</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Wiest</surname><given-names initials="K">Katharina</given-names></name><degrees>PhD</degrees><xref rid="A3" ref-type="aff">3</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Hoffman</surname><given-names initials="K">Kim</given-names></name><degrees>PhD</degrees><xref rid="A1" ref-type="aff">1</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Pertl</surname><given-names initials="K">Kellie</given-names></name><degrees>MPH</degrees><xref rid="A3" ref-type="aff">3</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Petluri</surname><given-names initials="R">Ritwika</given-names></name><degrees>BS</degrees><xref rid="A3" ref-type="aff">3</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>McCarty</surname><given-names initials="D">Dennis</given-names></name><degrees>PhD</degrees><xref rid="A4" ref-type="aff">4</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Korthuis</surname><given-names initials="PT">P. Todd</given-names></name><degrees>MD MPH</degrees><xref rid="A1" ref-type="aff">1</xref><xref rid="A4" ref-type="aff">4</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Martin</surname><given-names initials="SA">Stephen A.</given-names></name><degrees>MD EdM</degrees><xref rid="A3" ref-type="aff">3</xref><xref rid="A5" ref-type="aff">5</xref></contrib></contrib-group><aff id="A1"><label>1</label>Division of General Internal Medicine and Geriatrics, Section of Addiction Medicine, Oregon Health &amp; Science University, Portland, OR</aff><aff id="A2"><label>2</label>Central City Concern, Portland OR</aff><aff id="A3"><label>3</label>Boulder Care, Portland OR</aff><aff id="A4"><label>4</label>School of Public Health, Oregon Health &amp; Science University and Portland State University, Portland OR</aff><aff id="A5"><label>5</label>Department of Family Medicine and Community Health, UMass Chan Medical School, Worcester MA</aff><author-notes><corresp id="CR1"><bold>Corresponding Author:</bold> Brian Chan MD MPH, Associate Professor of Medicine, Section of Addiction Medicine, Division of General Internal Medicine &amp; Geriatrics, Oregon Health &amp; Science University, 3181 SW Sam Jackson Road, L-475, Fax: 503-494-0979, <email>chanbri@ohsu.edu</email></corresp></author-notes><pub-date pub-type="ppub"><month>12</month><year>2024</year></pub-date><pub-date pub-type="epub"><day>05</day><month>9</month><year>2024</year></pub-date><volume>167</volume><issue-id pub-id-type="pmc-issue-id">486679</issue-id><fpage>209511</fpage><lpage>209511</lpage><pub-history><event event-type="nihms-submitted"><date><day>03</day><month>04</month><year>2025</year></date></event><event event-type="pmc-release"><date><day>16</day><month>04</month><year>2025</year></date></event><event event-type="pmc-live"><date><day>16</day><month>04</month><year>2025</year></date></event><event event-type="pmc-last-change"><date iso-8601-date="2025-04-17 11:25:33.553"><day>17</day><month>04</month><year>2025</year></date></event></pub-history><self-uri xmlns:xlink="http://www.w3.org/1999/xlink" content-type="pmc-pdf" xlink:href="nihms-2067490.pdf"/><abstract id="ABS1"><sec id="S1"><title>Introduction:</title><p id="P1">At the beginning of the COVID-19 pandemic, federal agencies permitted telehealth initiation of buprenorphine treatment for opioid use disorder (OUD) without in-person assessment. It remains unclear how telehealth-only buprenorphine treatment impacts time to discontinuation and patient reported treatment outcomes.</p></sec><sec id="S2"><title>Methods:</title><p id="P2">A longitudinal observational cohort study conducted September 2021 through March 2023 enrolled participants with OUD initiating buprenorphine (&#8804; 45 days) with internet and phone access in Oregon and Washington. The intervention was a fully telehealth-only (THO) app versus treatment as usual (TAU) in office-based settings with some telehealth. We assessed self-reported buprenorphine discontinuation at 4-,12-, and 24-weeks. Generalized estimating equations (GEE) calculated unadjusted and adjusted relative risk ratios (RR) for discontinuation averaged over the study period. Secondary outcomes included change in the Brief Addiction Monitor (BAM) and the visual analogue craving scale. Generalized linear models estimated average within-group and between-group differences over time.</p></sec><sec id="S3"><title>Results:</title><p id="P3">Participants (n=103 THO; n=56 TAU) had a mean age of 37 years (SD=9.8 years) and included 52% women, 83% with Medicaid insurance, 80% identified as White, 65% unemployed/student, and 19% unhoused. There were differences in gender (THO = 54% women vs. TAU = 44%, <italic toggle="yes">p</italic>=0.04), unemployed status (60% vs 75%, <italic toggle="yes">p</italic>=.02), and stable housing (84% vs 73%, <italic toggle="yes">p</italic>=0.02). Rates of buprenorphine discontinuation were low in the THO (4%) and TAU (13%) groups across 24 weeks. In the adjusted analysis, the risk of discontinuation was 61% lower in the THO group (aRR=0.39, 95% CI [0.17, 0.89], <italic toggle="yes">p</italic>=.026). Decreases occurred over time on the harms subscale of the BAM (within-group difference &#8722;0.85, <italic toggle="yes">p</italic>=0.0004 [THO], and &#8722;0.68, <italic toggle="yes">p</italic>=0.04 [TAU]) and cravings (within-group difference &#8722;13.47, <italic toggle="yes">p</italic>=0.0001 [THO] vs &#8722;7.65, <italic toggle="yes">p</italic>=0.01 [TAU]).</p></sec><sec id="S4"><title>Conclusions:</title><p id="P4">A telehealth-only platform reduced the risk of buprenorphine discontinuation compared to office-based TAU. In-person evaluation to receive buprenorphine may not be necessary for treatment-seeking patients.</p></sec></abstract><kwd-group><kwd>telemedicine</kwd><kwd>opioid use disorder</kwd><kwd>medications for opioid use disorder</kwd></kwd-group><custom-meta-group><custom-meta><meta-name>pmc-status-qastatus</meta-name><meta-value>0</meta-value></custom-meta><custom-meta><meta-name>pmc-status-live</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-status-embargo</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-status-released</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-open-access</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-olf</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-manuscript</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-legally-suppressed</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-has-pdf</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-has-supplement</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-pdf-only</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-suppress-copyright</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-is-real-version</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-is-scanned-article</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-preprint</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-in-epmc</meta-name><meta-value>yes</meta-value></custom-meta></custom-meta-group></article-meta></front></article></pmc-articleset>